Literature DB >> 20018349

Lymphovascular invasion and pT stage are prognostic factors in patients treated with radical nephroureterectomy for localized upper urinary tract transitional cell carcinoma.

Dong Suk Kim1, Young Hoon Lee, Kang Su Cho, Nam Hoon Cho, Byung Ha Chung, Sung Joon Hong.   

Abstract

OBJECTIVES: To investigate the prognostic significance of lymphovascular invasion (LVI) in patients with localized upper urinary tract transitional cell carcinoma (UUT-TCC) after radical nephroureterectomy.
METHODS: The clinical records of 271 patients with UUT-TCC who underwent radical nephroureterectomy between 1986 and 2006 were reviewed. Patients with pT4 stage, lymph node involvement, or distant metastasis were excluded. A total of 238 patients with pTa-3N0M0 were eligible. The prognostic significance of various clinicopathologic factors was analyzed using univariate and multivariate analysis. The mean age was 64.1 years (range, 25-91 years) and the median follow-up duration was 53.4 months (range, 3-240 months).
RESULTS: LVI was present in 31 patients (13%). LVI was related to higher pT stage, high tumor grade, sessile architecture, and squamous differentiation. On univariate analysis, tumor architecture, squamous differentiation, LVI, tumor grade, and pT stage influenced disease-specific survival. On multivariate analysis, LVI (hazards ratio [HR], 2.33; P = .014) and pT stage (HR, 2.07; P = .021) showed significantly different rates of disease-specific survival. Patients were classified according to pT stage and LVI. The high-risk group (pT3 and LVI+) showed significantly worse disease-specific survival than the low- (pT < or = 2 and LVI-) or intermediate-risk groups (pT3 and LVI-, pT < or = 2 and LVI+) (P <.001 and P = .032, respectively).
CONCLUSIONS: LVI and pT stage are significant prognostic factors for recurrence-free and cancer-specific survivals in patients with localized UUT-TCC. LVI and pT stage would be helpful for selecting patients who are appropriate for postoperative adjuvant chemotherapy. 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20018349     DOI: 10.1016/j.urology.2009.07.1350

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  20 in total

1.  [Urothelial carcinoma of the upper urinary tract: clinical and pathological criteria and their predictive implications after radical nephroureterectomy].

Authors:  Christian Seitz; Paul Schramek
Journal:  Wien Med Wochenschr       Date:  2011-08

2.  Canadian guidelines for postoperative surveillance of upper urinary tract urothelial carcinoma.

Authors:  Anil Kapoor; Christopher B Allard; Peter Black; Wassim Kassouf; Christopher Morash; Ricardo Rendon
Journal:  Can Urol Assoc J       Date:  2013 Sep-Oct       Impact factor: 1.862

3.  Upper urinary tract urothelial carcinoma: what have we learned in the last 4 years?

Authors:  Mesut Remzi; Shahrokh Shariat; Wilhelm Huebner; Harun Fajkovic; Christian Seitz
Journal:  Ther Adv Urol       Date:  2011-04

Review 4.  Prognostic factors for upper urinary tract urothelial carcinoma.

Authors:  Thomas F Chromecki; Karim Bensalah; Mesut Remzi; Grégory Verhoest; Eugene K Cha; Douglas S Scherr; Giacomo Novara; Pierre I Karakiewicz; Shahrokh F Shariat
Journal:  Nat Rev Urol       Date:  2011-07-05       Impact factor: 14.432

5.  The result of adjuvant chemotherapy for localized pT3 upper urinary tract carcinoma in a multi-institutional study.

Authors:  Atsunari Kawashima; Yasutomo Nakai; Masashi Nakayama; Takeshi Ujike; Go Tanigawa; Yutaka Ono; Akihito Kamoto; Tsuyosi Takada; Yuichiro Yamaguchi; Hitoshi Takayama; Kazuo Nishimura; Norio Nonomura; Akira Tsujimura
Journal:  World J Urol       Date:  2011-10-09       Impact factor: 4.226

Review 6.  Oncologic outcomes obtained after neoadjuvant and adjuvant chemotherapy for the treatment of urothelial carcinomas of the upper urinary tract: a review.

Authors:  Jan Cordier; Guru Sonpavde; Christian G Stief; Derya Tilki
Journal:  World J Urol       Date:  2012-09-29       Impact factor: 4.226

Review 7.  Predictive factors of recurrence and survival of upper tract urothelial carcinomas.

Authors:  Grégory Verhoest; Shahrokh F Shariat; Thomas F Chromecki; Jay D Raman; Vitaly Margulis; Giacomo Novara; Christian Seitz; Mesut Remzi; Morgan Rouprêt; Douglas S Scherr; Karim Bensalah
Journal:  World J Urol       Date:  2011-06-17       Impact factor: 4.226

8.  The oncologic impact of a delay between diagnosis and radical nephroureterectomy due to diagnostic ureteroscopy in upper urinary tract urothelial carcinomas: results from a large collaborative database.

Authors:  Laurent Nison; Morgan Rouprêt; Grégory Bozzini; Adil Ouzzane; François Audenet; Géraldine Pignot; Alain Ruffion; Jean-Nicolas Cornu; Sophie Hurel; Antoine Valeri; Mathieu Roumiguie; Thomas Polguer; Nicolas Hoarau; Olivier Mérigot de Treigny; Evanguelos Xylinas; Alexandre Matte; Stéphane Droupy; Pierre Olivier Fais; Aurélien Descazeaud; Pierre Colin
Journal:  World J Urol       Date:  2012-10-16       Impact factor: 4.226

9.  Squamous differentiation and prognosis in upper urinary tract urothelial carcinoma.

Authors:  Naohiro Makise; Teppei Morikawa; Taketo Kawai; Tohru Nakagawa; Haruki Kume; Yukio Homma; Masashi Fukayama
Journal:  Int J Clin Exp Pathol       Date:  2015-06-01

10.  Association between lymphovascular invasion and oncologic outcomes among upper urinary tract urothelial carcinoma patients who underwent radical nephroureterectomy.

Authors:  Sang Hun Song; Chang Hee Ye; Sangchul Lee; Sung Kyu Hong; Seok-Soo Byun; Sang Eun Lee; Jong Jin Oh
Journal:  J Cancer Res Clin Oncol       Date:  2019-09-09       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.